PD-1 and TIGIT coexpression identifies a circulating CD8 T cell subset predictive of response to anti-PD-1 therapy

Background Clinical benefit from programmed cell death 1 receptor (PD-1) inhibitors relies on reinvigoration of endogenous antitumor immunity. Nonetheless, robust immunological markers, based on circulating immune cell subsets associated with therapeutic efficacy are yet to be validated.Methods We i...

Full description

Saved in:
Bibliographic Details
Main Authors: Paul Nghiem, Martin Cheever, Stanley R Riddell, Steven P Fling, Nirasha Ramchurren, Nathalie Labarrière, Sylvain Simon, Virginie Vignard, Tiffany Beauvais, Brigitte Dreno, Valentin Voillet, Zhong Wu, Camille Dabrowski, Nicolas Jouand, Amir Khammari, Cécile Braudeau, Régis Josien, Olivier Adotevi, Caroline Laheurte, François Aubin, Charles Nardin, Samuel Rulli, Raphael Gottardo, Candice D Church
Format: Article
Language:English
Published: BMJ Publishing Group 2020-10-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/8/2/e001631.full
Tags: Add Tag
No Tags, Be the first to tag this record!